Resveratrol corrects aberrant splicing of RYR1 pre-mRNA and Ca2+ signal in myotonic dystrophy type 1 myotubes

Resveratrol corrects aberrant splicing of RYR1 pre-mRNA and Ca2+ signal in myotonic dystrophy type 1 myotubes

Myotonic dystrophy type 1 (DM1) is a spliceopathy related to the mis-splicing of several genes caused by sequestration of nuclear transcriptional RNA-binding factors from non-coding CUG repeats of DMPK pre-mRNAs. Dysregulation of ryanodine receptor 1 (RYR1), sarcoplasmatic/endoplasmatic Ca2+-ATPase...

Full description

Bibliographic Details
Main Authors:	Massimo Santoro, Roberto Piacentini, Alessia Perna, Eugenia Pisano, Anna Severino, Anna Modoni, Claudio Grassi, Gabriella Silvestri
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2020-01-01
Series:	Neural Regeneration Research
Subjects:	alternative splicing; calcium homeostasis; cug-bp1; foci; mbnl1; myotonic dystrophy type 1; myotubes; resveratrol
Online Access:	http://www.nrronline.org/article.asp?issn=1673-5374;year=2020;volume=15;issue=9;spage=1757;epage=1766;aulast=Santoro

Similar Items

Zebrafish mbnl mutants model physical and molecular phenotypes of myotonic dystrophy
by: Melissa N. Hinman, et al.
Published: (2021-06-01)

Sustainable recovery of MBNL activity in autoregulatory feedback loop in myotonic dystrophy
by: Zuzanna Rogalska, et al.
Published: (2022-12-01)

Loss of MBNL1-mediated retrograde BDNF signaling in the myotonic dystrophy brain
by: Pei-Ying Wang, et al.
Published: (2023-03-01)

Calcitriol increases MBNL1 expression and alleviates myotonic dystrophy phenotypes in HSALR mouse models
by: Kun Huang, et al.
Published: (2022-12-01)

An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I
by: Andrea López-Martínez, et al.
Published: (2020-09-01)

Cognate RNA-Binding Modes by the Alternative-Splicing Regulator MBNL1 Inferred from Molecular Dynamics
by: Àlex L. González, et al.
Published: (2022-12-01)

Deciphering the mechanisms underlying brain alterations and cognitive impairment in congenital myotonic dystrophy
by: Thiéry De Serres-Bérard, et al.
Published: (2021-12-01)

BlockmiR AONs as Site-Specific Therapeutic MBNL Modulation in Myotonic Dystrophy 2D and 3D Muscle Cells and HSA<sup>LR</sup> Mice
by: Sarah J. Overby, et al.
Published: (2023-03-01)

Splicing of human chloride channel 1
by: Takumi Nakamura, et al.
Published: (2016-03-01)

Disrupting the Molecular Pathway in Myotonic Dystrophy
by: Xiaomeng Xing, et al.
Published: (2021-12-01)

Effects of Physiological Doses of Resveratrol and Quercetin on Glucose Metabolism in Primary Myotubes
by: Itziar Eseberri, et al.
Published: (2021-01-01)

Altered levels of the splicing factor muscleblind modifies cerebral cortical function in mouse models of myotonic dystrophy
by: Gang Chen, et al.
Published: (2018-04-01)

Nuclear Envelope Transmembrane Proteins in Myotonic Dystrophy Type 1
by: Stefan Hintze, et al.
Published: (2018-10-01)

Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy
by: Estefanía Cerro-Herreros, et al.
Published: (2021-12-01)

Generation and Neuronal Differentiation of hiPSCs From Patients With Myotonic Dystrophy Type 2
by: Paola Spitalieri, et al.
Published: (2018-07-01)

LDB3 splicing abnormalities are specific to skeletal muscles of patients with myotonic dystrophy type 1 and alter its PKC binding affinity
by: Yoshihiro Yamashita, et al.
Published: (2014-09-01)

Transcriptome Analysis Reveals Altered Inflammatory Pathway in an Inducible Glial Cell Model of Myotonic Dystrophy Type 1
by: Cuauhtli N. Azotla-Vilchis, et al.
Published: (2021-01-01)

A Patient with Myotonic Dystrophy Type 1 Presenting as Parkinsonism
by: Ji-Hyun Choi, et al.
Published: (2018-09-01)

Optical Mapping Approaches on Muscleblind‐Like Compound Knockout Mice for Understanding Mechanistic Insights Into Ventricular Arrhythmias in Myotonic Dystrophy
by: Chung‐Chuan Chou, et al.
Published: (2017-04-01)

Circulating Irisin Is Reduced in Male Patients with Type 1 and Type 2 Myotonic Dystrophies
by: Elena Dozio, et al.
Published: (2017-11-01)

MBNL1-Associated Mitochondrial Dysfunction and Apoptosis in C2C12 Myotubes and Mouse Skeletal Muscle
by: Shingo Yokoyama, et al.
Published: (2020-09-01)

Block or degrade? Balancing on- and off-target effects of antisense strategies against transcripts with expanded triplet repeats in DM1
by: Najoua El Boujnouni, et al.
Published: (2023-06-01)

Effect of Resveratrol on Mitochondrial Biogenesis and Muscle Fiber Type Transformation in Bovine Myotubes via SIRT1/PGC-1α
by: ZHANG Jingyue, DONG Pengcheng, ZUO Huixin, LIANG Rongrong, MAO Yanwei, ZHANG Yimin, YANG Xiaoyin, LUO Xin, ZHU Lixian
Published: (2024-02-01)

Pattern retinal dystrophy in a case of myotonic dystrophy
by: Chahveer Singh Bindra, et al.
Published: (2023-01-01)

Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression
by: Irene González-Martínez, et al.
Published: (2023-12-01)

Myostatin Increases Smad2 Phosphorylation and Atrogin-1 Expression in Chick Embryonic Myotubes
by: Takaoki Saneyasu, et al.
Published: (2019-07-01)

Editorial: Myotonic Dystrophies: Developments in Research From Bench to Bedside
by: Gabriella Silvestri, et al.
Published: (2020-09-01)

Fluid Biomarkers of Central Nervous System (CNS) Involvement in Myotonic Dystrophy Type 1 (DM1)
by: Salvatore Rossi, et al.
Published: (2023-01-01)

Myotonic Dystrophy Type 1 with Syringomyelia in a Young Patient
by: Xiao-Lin Yu, et al.
Published: (2016-01-01)

Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1
by: Thiéry De Serres-Bérard, et al.
Published: (2022-11-01)

Effects of Insulin-Like Growth Factor-I on the Expression of Atrogin-1/MAFbx in Chick Myotube Cultures
by: Kazuki Nakashima, et al.
Published: (2017-07-01)

Abnormal Cortical Thickness Is Associated With Deficits in Social Cognition in Patients With Myotonic Dystrophy Type 1
by: Laura Serra, et al.
Published: (2020-02-01)

N-acetyl-L-cysteine Prevents Lactate-Mediated PGC1-alpha Expression in C2C12 Myotubes
by: Minas Nalbandian, et al.
Published: (2019-06-01)

Small Molecules Which Improve Pathogenesis of Myotonic Dystrophy Type 1
by: Marta López-Morató, et al.
Published: (2018-05-01)

Clinical and Molecular Insights into Gastrointestinal Dysfunction in Myotonic Dystrophy Types 1 & 2
by: Janel A. M. Peterson, et al.
Published: (2022-11-01)

Transcranial brain parenchyma sonographic findings in patients with myotonic dystrophy type 1 and 2
by: Milija Mijajlovic, et al.
Published: (2024-03-01)

Therapeutic Targeting of the GSK3β-CUGBP1 Pathway in Myotonic Dystrophy
by: Maggie Lutz, et al.
Published: (2023-06-01)

Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2
by: Lubov Timchenko
Published: (2022-09-01)

Inhibition of Postn Rescues Myogenesis Defects in Myotonic Dystrophy Type 1 Myoblast Model
by: Xiaopeng Shen, et al.
Published: (2021-08-01)

Molecular genetics of congenital myotonic dystrophy
by: Stella Lanni, et al.
Published: (2019-12-01)